Prostate Cancer

Talzenna Plus Xtandi lengthened time to progression in men with metastatic castration-resistant prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about survivorship in prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about the long-term effects associated with a prostate cancer diagnosis.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about PSMA, what it is and how it is advancing the prostate cancer landscape.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about the importance of patient-physician communication in prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about seeking support after a prostate cancer diagnosis.

Men with metastatic castration-resistant prostate cancer lived longer without their disease progressing when treated with Rubraca compared to standard of care.

Men with prostate cancer who were “fast metabolizers” of caffeine from coffee tended to have better prostate cancer-specific survival, according to recent research.

When talking about cancer, it’s OK to use profanities sometimes.

From NFL Hall of Famer Shannon Sharpe and Monty Python member sharing their cancer diagnoses to “Good Morning America” promoting Be The Match, here’s what’s happening in the cancer space this week.

When my husband was diagnosed with prostate cancer in his mid 40s, we opted for a more aggressive treatment strategy, which led him being cancer-free and able to enjoy a healthy sex life.

Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant prostate cancer.

BNT211-01, a novel CAR-T cell therapy, was efficacious in treating patients with CLDN6-positive, relapsed/refractory solid cancers, according to a small clinical trial.

From actress Jane Fonda giving an update on her cancer, to a patient with leukemia proving he was at the Sept. 11 attacks in New York City with an old newspaper clipping, here’s what’s happening in the cancer space this week.

There’s a flip side to the trauma of cancer — a better appreciation of the small things in everyday life.

Even though I had no symptoms, my prostate cancer was caught thanks to frequent follow-ups with my doctor.

I recently was asked to speak at a banquet for my cancer center and saw that as a great opportunity to recognize those who cared for me.

From the death of a football Hall of Famer and a golf champion to actress and former Nickelodeon star Jennette McCurdy discussing her mother’s breast cancer in her memoir, “I’m Glad My Mom Died,” here’s what’s happening in the cancer space this week.

Radiotherapy with standard of care for the treatment of patients with low-burden metastatic prostate cancer had minimal effects on quality of life over a five-year follow-up period.

From ESPN analyst Dick Vitale announcing he is cancer-free months following a lymphoma diagnosis to a Speedo-clad race in South Africa to raise awareness for cancer, here’s what’s happening in the oncology space this week.

If approved, the Lynparza-based regimen would become the first combination of a PARP inhibitor and a hormonal agent for metastatic castration-resistant prostate cancer.

I was shocked at a recent doctor appointment when practically nobody in the office was wearing a mask.

Joseph Wood and his caregiver, Deborah Wood, provide advice for patients and caregivers with prostate cancer who may be in similar situations, and comment on the support they have received from their family and community.

Treatment with an investigational drug plus with Libtayo showed encouraging anti-tumor activity in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary data from an early-phase trial.

Keytruda plus chemotherapy failed to best the chemotherapy docetaxel alone in patients with metastatic castration-resistant prostate cancer, according to findings of a study of more than 1,000 patients.

Joseph Wood and his wife and caregiver, Deborah, share their concerns and questions about radioligand therapy and how the COVID-19 pandemic has impacted their treatment experience.

The Food and Drug Administration approved oral Nubeqa plus the chemotherapy docetaxel for patients with metastatic hormone-sensitive prostate cancer.

Treatment with primary radiotherapy was linked to an increased risk for the development of secondary primary cancers among a large group of men with localized prostate cancer, according to recent study findings.

Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer (mCRPC).